Form 4: Nexalin Technology Chief Medical Officer Acquires Shares
SEC Form 4 Filing
David Owens, Chief Medical Officer of Nexalin Technology, Inc., purchased 1,619 shares of common stock at $0.71 per share on June 18, 2024.
Summary
- On June 18, 2024, David Owens, the Chief Medical Officer of Nexalin Technology, Inc. (NXL), acquired 1,619 shares of common stock.
- The purchase price was $0.71 per share.
- Following the transaction, Owens directly owns 145,793 shares of Nexalin Technology, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. An insider purchase is generally a good sign, but the amount is relatively small.
Positives
- The purchase of shares by a company insider can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider trading activity is closely monitored by regulators and investors as it can provide insights into the company's performance and future prospects. Form 4 filings are a routine part of this monitoring process.
Stakeholder Impact
- The insider purchase could have a slightly positive impact on shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 06/18/2024 | Date of transaction: David Owens purchased shares of Nexalin Technology, Inc. |
| 06/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.